major
public
health
problem
affect
estim
million
individu
worldwid
wwwunaidsorg
although
year
sinc
identifi
etiolog
caus
acquir
immun
defici
syndrom
aid
effect
vaccin
avail
thu
apart
public
health
measur
aim
prevent
effect
strategi
control
infect
lower
transmiss
use
antiretrovir
drug
either
treatment
prevent
infect
current
antiretrovir
drug
belong
four
class
nucleosidenucleotid
revers
transcriptas
inhibitor
nrti
nonnucleosid
revers
transcriptas
inhibitor
nnrti
proteas
pr
inhibitor
pi
fusion
inhibitor
vivetboud
et
al
de
clercq
abdelrahman
et
al
manfredi
sabbatani
nrti
nnrti
respect
competit
alloster
inhibitor
revers
transcriptas
rt
act
earli
viral
lifecycl
block
convers
viral
rna
genom
doubl
strand
provir
dna
precursor
shehuxhilaga
et
al
fuzeon
enfuvirtid
peptid
also
act
earli
viru
lifecycl
prevent
viral
entri
interact
transmembran
protein
shehuxhilaga
et
al
contrast
pi
inhibit
late
stage
viru
replic
block
specif
cleavag
gag
gagpol
polyprotein
matur
structur
protein
enzym
shehuxhilaga
et
al
earli
antiretrovir
regimen
consist
one
two
rti
deliv
sequenti
monotherapi
led
treatment
failur
piacenti
advent
combin
therapi
highli
activ
antiretrovir
therapi
haart
sinc
respons
dramat
decreas
aid
mortal
palella
et
al
current
haart
regimen
gener
compris
three
antiretrovir
drug
usual
two
nrti
either
pi
nnrti
yeni
et
al
armouri
agent
avail
treatment
patient
new
drug
drug
target
need
identifi
due
drug
toxic
eventu
emerg
drug
resist
strain
current
antiretrovir
inhibitor
clavel
hanc
moreov
resist
one
drug
normal
result
crossresist
inhibitor
class
render
larg
number
agent
limit
clinic
use
clavel
hanc
therefor
develop
avail
new
drug
fuzeon
integras
inhibitor
raltegravir
grinsztejn
et
al
antagonist
maraviroc
stephenson
remain
activ
drug
resist
viru
essenti
continu
success
haart
yeni
increas
understand
reproduc
interact
host
cell
machineri
result
identif
potenti
drug
target
exploit
develop
new
class
inhibitor
describ
strategi
agent
block
late
stage
replic
includ
synthesi
traffick
viral
polyprotein
viral
assembl
matur
bud
novel
approach
block
oligomer
viral
enzym
interact
viral
protein
host
cell
factor
discuss
includ
feasibl
drug
target
peptidomimet
pi
act
late
stage
replic
block
viral
matur
review
deal
agent
inhibit
pr
novel
mechan
distinct
transit
state
mimet
competit
inhibitor
pr
follow
viru
attach
fusion
uncoat
singl
strand
posit
sens
rna
genom
revers
transcrib
viral
rt
provir
dna
precursor
revers
transcript
complex
rtc
contain
viral
possibl
host
cell
factor
fig
rtc
matur
preintegr
complex
pic
traffic
nucleu
viral
cdna
insert
host
cell
chromosom
integras
telesnitski
goff
process
entri
includ
integr
defin
earli
step
viral
life
cycl
late
stage
viru
replic
begin
transcript
viral
mrna
integr
proviru
fig
singli
multipli
splice
mrna
encod
envelop
protein
regulatoryaccessori
protein
respect
rabson
grave
gag
gagpol
polyprotein
translat
unsplic
mrna
swanstrom
format
two
type
polyprotein
unsplic
mrna
mediat
ribosom
frameshift
mechan
bring
pol
sequenc
read
frame
gag
perturb
ribosom
frameshift
lead
chang
gag
gagpol
ratio
detriment
viru
assembl
morphogenesi
releas
swanstrom
gag
encod
viral
structur
protein
matrix
capsid
ca
nucleocapsid
nc
two
spacer
peptid
gagpol
also
encod
ca
nc
addit
three
viral
enzym
pr
rt
translat
gag
gagpol
target
host
cell
plasma
membran
process
depend
myristoyl
nterminu
gag
fig
swanstrom
inhibit
myristoyl
disrupt
proper
target
gag
gagpol
plasma
membran
swanstrom
gaggag
gaggagpol
gagrna
interact
also
essenti
proper
assembl
matur
infecti
virion
gag
gagpol
assembl
plasma
membran
along
viral
envelop
glycoprotein
form
immatur
viral
particl
fig
gag
necessari
suffici
viru
particl
format
freed
swanstrom
viral
genom
rna
also
packag
virion
interact
nc
gag
psi
packag
signal
genom
swanstrom
newli
assembl
virion
bud
cell
believ
gagpol
polyprotein
oligomer
order
activ
pr
form
activ
pr
homodim
result
sequenti
cleavag
gag
gagpol
matur
structur
protein
enzym
kaplan
et
al
pettit
et
al
agent
bind
domain
gag
gagpol
modul
oligomer
like
neg
effect
viru
assembl
matur
bud
fig
agent
interfer
pr
mediat
cleavag
gag
gagpol
result
product
immatur
viral
particl
noninfecti
kohl
et
al
viru
particl
bud
egress
mediat
interact
viral
protein
late
domain
compon
endosom
sort
machineri
ion
channel
form
viral
protein
u
vpu
also
facilit
viral
particl
egress
host
cell
describ
detail
specif
process
requir
viral
assembl
matur
bud
agent
describ
block
step
gag
gagpol
polyprotein
encod
overlap
open
read
frame
unsplic
mrna
translat
gagpol
synthes
ribosom
frameshift
mechan
occur
frequenc
gag
translat
event
jack
et
al
similar
frameshift
mechan
also
use
retrovirus
includ
rou
sarcoma
viru
mous
mammari
tumor
viru
order
regul
express
gagpol
jack
varmu
jack
et
al
jack
et
al
frameshift
site
heptanucleotid
aurich
sequenc
uuuuuua
found
end
nc
code
sequenc
conserv
amongst
isol
slipperi
sequenc
downstream
rna
stem
loop
structur
stall
ribosom
synthesi
gag
allow
ribosom
slip
back
one
nucleotid
enabl
synthesi
gagpol
fusion
protein
jack
et
al
sequenc
stemloop
structur
stabil
adjac
interact
sequenc
believ
key
compon
frameshift
signal
jack
et
al
kollmu
et
al
hill
et
al
detail
recent
report
nmr
structur
analysi
current
frameshift
model
recent
review
brierley
do
ramo
studi
demonstr
perturb
gaggagpol
ratio
result
major
defect
viru
replic
suggest
interf
ribosom
frameshift
repres
viabl
drug
target
alter
gaggagpol
ratio
engin
vector
gag
pol
gene
open
read
frame
result
major
defect
assembl
bud
karacosta
et
al
park
morrow
block
viru
assembl
partial
overcom
inhibit
pr
suggest
increas
pr
activ
respons
defect
karacosta
et
al
later
studi
impact
decreas
ratio
gaggagpol
virion
product
determin
cotransfect
plasmid
express
gag
gagpol
alon
demonstr
mainten
ratio
import
replic
also
virion
rna
dimer
format
stabil
shehuxhilaga
et
al
furthermor
decreas
gagpol
translat
result
major
defect
viru
matur
infect
dulud
et
al
small
molecul
n
ndimethylpropyl
amidino
benzen
tetrahydrochlorid
tabl
thought
enhanc
ribosom
frameshift
bind
rna
stem
loop
structur
ribosom
frameshift
signal
result
increas
ribosom
paus
hung
et
al
imbal
result
gaggagpol
ratio
associ
inhibit
acut
chronic
infect
ccrfcem
cell
peripher
blood
mononuclear
cell
late
phase
viral
life
cycl
gag
polyprotein
target
plasma
membran
believ
colocalis
lipid
raft
microdomain
assembl
immatur
virion
morikawa
et
al
bryant
ratner
bouamr
et
al
ding
et
al
holm
et
al
tang
et
al
membran
target
gag
mediat
ntermin
myristoyl
group
concert
conserv
basic
amino
acid
nterminu
domain
gag
bryant
ratner
fack
et
al
ono
freed
ono
et
al
myrist
acid
satur
fatti
acid
post
transat
attach
ntermin
glycin
gag
gagpol
verones
et
al
myristoyl
gag
gagpol
critic
target
polyprotein
plasma
membran
park
morrow
smith
et
al
mutat
interfer
gag
myristoyl
inhibit
viral
bud
misdirect
virion
assembl
cytosol
fraction
gottling
et
al
bryant
ratner
howev
complet
inhibit
gag
myristoyl
necessari
block
bud
morikawa
et
al
myristoyl
twostep
process
involv
activ
myrist
myristoylcoa
acylcoa
synthetas
transfer
myristoyl
moieti
myristoylcoa
substrat
ntermin
glycin
gag
enzym
nmyristoyltransferas
nmt
morikawa
et
al
verones
et
al
pathway
util
deliv
altern
myristoyl
substrat
perturb
viral
assembl
myrist
acid
analogu
acid
potent
inhibitor
product
acut
chronic
infect
tcell
line
exhibit
maximum
inhibitori
effect
noncytotox
concentr
howev
mechan
action
defin
devada
et
al
anoth
analogu
acid
reduc
replic
tcell
line
langner
et
al
heteroatomsubstitut
analog
myrist
acid
acid
acid
act
altern
substrat
gag
myristoyl
bryant
et
al
bryant
et
al
parang
et
al
prevent
membran
bind
modifi
gag
protein
bryant
et
al
bryant
et
al
heteroatom
substitut
analog
potent
inhibitor
ad
gag
efficaci
similar
myrist
alter
viral
polyprotein
process
suggest
consequ
inhibit
gag
gagpol
traffick
bryant
et
al
acut
infect
tcell
line
reduc
replic
rang
bryant
et
al
also
inhibit
viral
product
chronic
infect
cell
consist
inhibitor
target
late
stage
replic
bryant
et
al
exhibit
synergist
effect
azt
suggest
potenti
use
combin
therapi
bryant
et
al
therapeut
efficaci
enhanc
conjug
glycerophospholipid
pidgeon
et
al
select
heteroatom
analog
target
protein
depend
posit
substitut
heteroatom
thu
exploit
therapeut
antiretrovir
strategi
nevertheless
heteroatomsubstitut
myrist
acid
analog
still
expect
advers
affect
substanti
rang
cellular
process
depend
protein
nmyristoyl
lindwass
resh
altern
strategi
target
gag
myristoyl
exogen
treatment
cell
unsatur
fatti
acid
includ
acid
physeter
acid
acid
goshuy
acid
lindwass
resh
lipid
raft
prefer
satur
fatti
acid
treatment
unsatur
analog
interfer
membran
target
gag
consequenti
viral
assembl
product
lindwass
resh
inhibitor
also
interfer
certain
srckinas
mediat
cellular
pathway
although
appear
effect
cell
prolifer
campbel
vogt
suggest
direct
dietari
intak
physeter
acid
goshuy
acid
could
use
therapeut
strategi
treatment
infect
howev
effect
long
term
intak
unsatur
fatti
acid
effect
nmyristoyl
signal
protein
src
gprotein
arf
heterogen
nacyl
retin
protein
need
assess
lindwass
resh
recent
studi
also
indic
role
phosphatidylinositid
pi
regul
gag
local
ono
et
al
bind
pi
domain
gag
activ
myristyol
switch
also
act
point
membran
attach
saad
et
al
bind
site
pi
highli
conserv
amongst
strain
therefor
repres
attract
antivir
target
shkriabai
et
al
saad
et
al
ca
play
import
role
lifecycl
promot
gaggag
interact
virion
matur
n
ctermin
domain
protein
serv
distinct
function
shown
mutat
analysi
n
termin
domain
ca
nca
otherwis
known
ntd
respons
maintain
proper
conform
ca
assembl
process
worthylak
et
al
li
et
al
ctermin
domain
ca
cca
ctd
critic
gaggag
interact
assembl
matur
gambl
et
al
gambl
et
al
describ
mutat
region
major
consequ
virion
matur
infect
von
schwedler
et
al
ganserpornillo
et
al
nmr
structur
ca
demonstr
protein
consist
mainli
seven
two
loop
structur
momani
et
al
gitti
et
al
five
form
coiledcoil
structur
one
locat
surfac
ntermin
domain
protein
momani
et
al
second
predict
form
cleavag
pr
tang
et
al
cleavag
ca
neighbour
protein
necessari
core
condens
conic
capsid
shell
format
vogt
wieger
et
al
compound
bind
region
would
expect
disrupt
proper
ca
shell
format
virion
infect
make
ca
import
attract
target
develop
antiretrovir
agent
proof
concept
studi
demonstr
potenti
inhibit
caca
interact
antiretrovir
target
publish
tang
et
al
comput
high
throughput
screen
small
molecul
librari
nmr
analysi
bind
specif
result
identif
bind
apic
site
ntd
immatur
matur
ca
tang
et
al
toxic
cell
reduc
viral
infect
releas
virion
lack
cone
shape
core
resembl
viral
particl
observ
express
mutat
disrupt
caca
interact
dorfman
et
al
reicin
et
al
von
schwedler
et
al
lanman
et
al
despit
aberr
viral
morpholog
affect
viral
particl
releas
proteolyt
process
tang
et
al
bind
common
site
within
ntd
thu
prevent
caca
interact
proper
gag
assembl
peptid
deriv
ca
also
describ
affect
viral
morphogenesi
interf
capsid
format
niedrig
et
al
synthet
peptid
paatleemmta
inhibit
replic
cell
cultur
assay
result
product
immatur
aberr
viral
particl
niedrig
et
al
tripeptid
amid
deriv
carboxyl
terminu
ca
inhibit
replic
three
potent
peptid
interact
ca
demonstr
capillari
electrophoresi
analysi
hoglund
et
al
glycylprolylglycineamid
interfer
format
particl
normal
conic
core
structur
hoglund
et
al
activ
metabolit
indic
latter
act
prodrug
andersson
et
al
howev
develop
resist
either
elus
suggest
peptid
mediat
effect
host
cell
factor
andersson
et
al
cai
small
peptid
select
phage
display
screen
act
inhibitor
assembl
immatur
gag
vitro
sticht
et
al
ternoi
et
al
cai
bind
cterminu
ca
kd
thu
prevent
necessari
conform
chang
ca
lead
format
matur
core
sticht
et
al
structur
cai
complex
ca
reveal
cai
bind
region
highli
conserv
hydrophob
pocket
within
c
terminu
ca
peptid
form
extra
bind
four
ca
ternoi
et
al
result
proteinpeptid
complex
therefor
five
bundl
reduc
caca
dimer
contact
destabil
dimer
interfac
bind
cai
cca
affect
assembl
immatur
capsid
particl
also
reduc
amount
correctli
assembl
matur
capsid
vitro
thu
act
promis
twostep
inhibitor
sticht
et
al
ctermin
domain
gag
context
gagpol
essenti
interact
gag
incorpor
virion
srinivasakumar
et
al
chiu
et
al
chien
et
al
sequenc
includ
highli
conserv
major
homolog
region
mhr
ca
domain
gag
adjac
srinivasakumar
et
al
chien
et
al
sequenc
also
critic
gag
assembl
drive
gag
oligomer
howev
magnitud
virion
incorpor
defect
gagpol
mhr
delet
mutant
vari
differ
studi
make
valu
target
region
gagpol
unclear
respect
inhibit
late
stage
replic
mammano
et
al
srinivasakumar
et
al
chiu
et
al
chien
et
al
sequenc
involv
gag
gagpol
interact
assum
similar
involv
gaggag
interact
howev
virion
gener
presenc
unlik
affect
gaggagpol
interact
defect
proteolyt
process
viru
virion
associ
rt
activ
observ
tang
et
al
prolin
rich
region
also
implic
packag
cleav
pol
protein
virion
suggest
mediat
host
cell
protein
dettenhof
yu
cen
et
al
identifi
host
cell
factor
implic
virion
incorpor
cleav
pol
necessari
establish
process
viabl
drug
target
nc
contain
two
highli
conserv
zinc
finger
motif
x
amino
acid
zinc
finger
nc
critic
earli
late
stage
replic
mutat
zinc
chelat
amino
acid
result
format
noninfecti
viru
aldovini
young
zinc
finger
requir
initi
elong
effici
templat
switch
revers
transcript
rodriguezrodriguez
et
al
tanchou
et
al
also
involv
genom
rna
dimer
cleavag
activ
coat
viral
rna
genom
protect
nucleas
lapadattapolski
et
al
given
critic
role
zinc
finger
replic
surpris
agent
coval
modifi
zinc
chelat
residu
describ
inhibitor
replic
rice
et
al
electrophil
disulfidesubstitut
benzamid
diba
inactiv
cell
free
viru
inhibit
earli
late
stage
replic
interf
revers
transcript
viral
particl
matur
rice
et
al
turpin
et
al
cell
line
treatment
diba
result
inhibit
viru
particl
releas
process
gag
product
virion
reduc
infect
turpin
et
al
defect
viral
particl
releas
matur
attribut
format
intermolecular
crosslinkag
zinc
finger
adjac
gag
molecul
therebi
prevent
effici
cleavag
pr
turpin
et
al
nondissoci
tether
dithian
compound
nsc
also
mediat
similar
defect
gag
process
rice
et
al
although
cellular
protein
also
contain
zinc
finger
inhibitor
appear
preferenti
target
retrovir
zinc
finger
may
explain
inaccess
inhibitor
appropri
cellular
compart
zinc
finger
contain
cellular
protein
locat
vivo
activ
zinc
finger
inhibitor
demonstr
transgen
murin
model
infecti
induc
integr
proviru
schito
et
al
recent
studi
nonhuman
primat
model
demonstr
reduct
level
peripher
blood
mononuclear
cell
therapi
zinc
finger
inhibitor
sacyl
thioester
samt
although
effect
viral
load
schito
et
al
studi
progress
optimis
bioavail
pharmacokinet
promis
inhibitor
much
understand
pr
domain
gagpol
activ
process
cascad
gag
gagpol
due
contribut
kaplan
colleagu
kaplan
et
al
pettit
et
al
strict
regul
pr
function
critic
effici
product
matur
viral
particl
prematur
activ
partial
inhibit
overexpress
pr
lead
major
defect
viral
assembl
product
noninfecti
viral
particl
krausslich
kaplan
et
al
karacosta
et
al
henc
novel
inhibitor
design
prevent
perturb
pr
dimer
could
potenti
inhibit
matur
pr
homodim
immatur
gagpol
embed
pr
pr
homodimer
aspartyl
proteas
form
symmetr
associ
two
amino
acid
subunit
crystal
structur
reveal
compact
predominantli
structur
short
region
near
c
terminu
wlodaw
et
al
dimer
pr
monom
gener
substratebind
pocket
catalyt
centr
essenti
pr
activ
cheng
et
al
pr
dimer
dissoci
constant
nm
gibb
free
energi
dimer
stabilis
kcalmol
oc
ph
nearli
bind
energi
contribut
fourstrand
form
n
ctermini
todd
et
al
fourstrand
compris
n
ctermini
pr
monom
repres
attract
drug
target
follow
reason
major
stabilis
region
activ
dimer
region
rel
free
known
pr
resist
mutat
sequenc
highli
conserv
isol
provid
uniqu
target
minimis
potenti
toxic
issu
eukaryot
aspartyl
proteas
gustchina
weber
standard
methodolog
analys
potenti
pr
inhibitor
prevent
pr
dimer
dissoci
inhibit
target
bind
pr
activ
site
competit
inhibit
describ
zhang
et
al
exampl
dissoci
inhibitor
ctermin
tetrapeptid
actlnf
exhibit
activ
micromolar
rang
ki
zhang
et
al
studi
also
shown
capac
n
ctermin
peptid
interfac
peptid
bind
pr
monom
thu
prevent
pr
dimer
activ
babe
et
al
franciskovich
et
al
schramm
et
al
schramm
et
al
identif
lead
peptid
provid
proof
concept
target
pr
region
constitut
viabl
strategi
develop
novel
inhibitor
pr
potenc
ctermin
tetrapeptid
increas
truncat
core
tripeptid
amino
acid
modif
addit
linear
hydrophob
moieti
palmitoyl
amino
terminu
peptid
lipid
moieti
thought
increas
dissoci
activ
peptid
direct
hydrophob
pr
interfac
schramm
et
al
howev
despit
capac
inhibit
pr
activ
low
nanomolar
concentr
lipopeptid
poorli
solubl
suscept
protein
degrad
modif
made
lipopeptid
make
less
peptidelik
caflisch
et
al
modifi
lipid
moieti
increas
solubl
retain
potenc
dumond
et
al
crosslink
interfaci
peptid
repres
anoth
strategi
aim
increas
affin
peptid
present
conform
similar
pr
monom
first
interfac
tetrapeptid
tether
glycin
linker
display
greater
potenc
compar
free
tetrapeptid
babe
et
al
approach
evolv
link
peptid
flexibl
alkyl
tether
zutshi
chmielewski
semirigid
alkyl
base
tether
ulyss
chmielewski
increas
distanc
peptid
approxim
pr
termini
dimer
conform
freedom
link
peptid
address
use
pyridinediol
naphthalen
base
molecularli
constrain
scaffold
boura
et
al
song
et
al
merabet
et
al
bannwarth
et
al
known
molecular
tong
compound
design
posit
interfac
peptid
clamp
termini
pr
monom
fig
studi
culmin
set
optimis
tong
symmetr
peptidomimet
sequenc
base
optimis
pr
ctermin
sequenc
tong
inhibit
activ
pr
either
sensit
resist
pi
ki
valu
cell
free
assay
bannwarth
et
al
variat
theme
interfac
peptid
includ
combin
advantag
lipopeptid
molecular
tong
interfac
peptid
link
lipophil
group
rigid
bicycl
guanidinium
scaffold
breccia
et
al
potent
compound
demonstr
pr
inhibitori
activ
similar
tether
peptid
molecular
tong
crosslink
interfaci
peptid
design
irrevers
inhibit
pr
format
disulfid
bond
peptid
conserv
pr
residu
demonstr
ki
low
micromolar
rang
zutshi
chmielewski
ctermin
tetrapeptid
also
tether
peptid
pr
activ
site
inhibitor
combin
dissoci
competit
method
inhibit
one
molecul
uhlikova
et
al
random
peptid
dissoci
inhibitor
pr
describ
bacteriophag
lambda
repressor
protein
utilis
develop
power
twohybrid
pr
dimer
assay
librari
random
peptid
identifi
potenti
pr
dimer
inhibitor
potent
peptid
identifi
pure
dissoci
inhibitor
low
ki
nm
park
rain
ultim
one
major
hurdl
develop
peptid
inhibitor
obtain
biolog
stabl
compound
deliv
insid
cell
one
mechan
achiev
fuse
peptid
amino
acid
sequenc
promot
either
encapsid
viral
particl
entri
host
cell
viru
protein
r
vpr
accessori
protein
packag
virion
tran
associ
gag
motif
viral
cellular
protein
success
deliv
viral
particl
vpr
fusion
protein
wu
et
al
inhibit
replic
report
fusion
vpr
viral
pr
recognit
sequenc
serio
et
al
express
pr
ctermin
tetrapeptid
vpr
fusion
vpr
spacer
tlnfoh
attenu
replic
chronic
infect
cell
singleround
replic
assay
carta
et
al
recent
inhibit
replic
demonstr
deliv
pr
interfac
peptid
fusion
peptid
utilis
tat
deriv
cell
permeabl
protein
transduct
domain
davi
et
al
peptid
pr
dimer
inhibitor
inhibit
activ
wildtyp
drug
resist
pr
cell
free
assay
valu
rang
peptid
success
deliv
chronic
infect
cell
reduc
viral
particl
product
observ
reduct
rather
inhibit
gag
process
suggest
peptid
may
interact
gagpol
embed
pr
disrupt
order
process
gagpol
lead
decreas
viral
particl
product
davi
et
al
local
elementari
structur
le
compris
strongli
interact
highli
conserv
amino
acid
usual
hydrophob
amino
acid
suggest
direct
fold
protein
nativ
conform
short
peptid
correspond
mimick
le
hypothesis
act
fold
inhibitor
prevent
protein
achiev
nativ
conform
broglia
et
al
peptid
identifi
le
pr
peptid
amino
acid
inhibit
pr
activ
ki
result
disorganis
pr
secondari
structur
reduc
content
broglia
et
al
broglia
et
al
current
effort
direct
toward
develop
shorter
less
hydrophob
peptid
mimet
base
lead
peptid
catalyt
inact
pr
monom
act
domin
neg
fashion
inhibit
wildtyp
pr
form
inact
heterodim
recombin
protein
assay
babe
craik
viru
express
pr
activ
site
mutat
cotransfect
wildtyp
viral
replic
viru
infect
reduc
babe
et
al
comput
model
use
success
design
optimis
dominantneg
pr
express
kww
mcphee
et
al
also
reduc
viral
replic
infect
junker
et
al
biochem
studi
recombin
domin
neg
pr
confirm
mechan
action
format
inact
heterodim
rozzel
et
al
interestingli
mutant
pr
homodimer
fold
express
wildtyp
pr
pr
heterodim
also
stabl
wildtyp
homodim
rozzel
et
al
henc
inact
pr
heterodim
form
domin
speci
domin
neg
strategi
inhibit
pr
would
requir
vivo
deliveri
genetherapi
system
therapeut
use
unlik
near
futur
screen
crude
extract
marin
organ
magenta
ascidian
didemnum
identifi
two
didemnaket
bicycl
ketal
b
linear
heptaprenoid
inhibit
pr
activ
valu
respect
pott
et
al
compound
unsuit
drug
candid
given
rise
novel
class
pentaest
potent
dissoci
inhibitor
pr
ki
fan
et
al
novel
class
pr
dimer
inhibitor
identifi
search
cambridg
structur
databas
pharmacophor
mimic
action
previous
identifi
inhibitori
interfac
peptid
quer
et
al
sever
triterpen
structur
identifi
ursol
acid
act
dissoci
inhibitor
pr
suggest
triterpen
could
provid
anoth
basic
scaffold
build
effect
peptidomimet
interestingli
anoth
member
triterpen
famili
act
novel
inhibitor
matur
discuss
later
review
mimet
test
abil
inhibit
pr
homodimer
perturb
format
song
et
al
mimet
rel
high
method
inhibit
appear
complex
howev
structur
provid
nonpeptid
lead
compound
pr
inhibitor
rate
specif
gag
cleavag
pr
depend
amino
acid
composit
differ
cleavag
site
recogn
viral
pr
swanstrom
base
order
proteolysi
pr
site
classifi
primari
secondari
maca
tertiari
cleavag
site
lack
process
site
pr
result
format
aberr
particl
swanstrom
particular
inhibit
cleavag
site
sever
consequ
core
format
stabil
virion
infect
pettit
et
al
wieger
et
al
pettit
et
al
shehuxhilaga
et
al
structur
stretch
cterminu
ca
nterminu
critic
virion
assembl
function
accola
et
al
clearli
pr
cleavag
site
potenti
target
antiretrovir
drug
design
regard
compound
interfer
viral
matur
block
cleavag
identifi
betulin
acid
bevirimat
potent
inhibit
matur
infect
li
et
al
zhou
et
al
specif
block
cleavag
cell
base
li
et
al
cell
free
assay
zhou
et
al
sakalian
et
al
thu
inhibit
core
condens
virion
matur
inhibit
gag
process
junction
result
gener
uncleav
product
transfect
cell
li
et
al
consist
propos
mechan
resist
select
long
term
cultur
presenc
betulin
acid
contain
mutat
region
flank
scissil
bond
adamson
et
al
zhou
et
al
mutat
site
gag
recogn
viral
pr
proteolysi
addit
singl
amino
acid
substitut
identifi
confer
resist
exclus
locat
either
c
terminu
ca
within
first
three
amino
acid
spacer
peptid
adamson
et
al
interestingli
confer
resist
independ
locat
within
boundari
protein
region
well
known
promot
gag
multimer
adamson
et
al
data
suggest
one
mechan
mutant
acquir
resist
success
undergon
phase
clinic
trial
current
phase
trial
test
efficaci
differ
dose
combin
approv
inhibitor
part
optimis
regimen
patient
fail
therapi
due
emerg
drug
resist
viru
like
enzym
rt
subunit
must
oligomer
form
activ
enzym
biolog
relev
form
present
virion
asymmetr
heterodim
compris
kda
kda
subunit
jacobomolina
et
al
kohlstaedt
et
al
rt
heterodim
extrem
stabl
extens
protein
surfac
area
buri
upon
subunit
dimer
thermodynam
measur
associ
rt
subunit
estim
gibb
free
energi
dimer
stabil
approxim
correspond
dissoci
constant
approxim
venezia
et
al
extens
review
rt
dimer
see
srivastava
et
al
region
upstream
downstream
pr
region
gagpol
investig
effect
pr
activ
bukovski
gottling
partin
et
al
loui
et
al
larg
delet
within
ctermin
truncat
rt
context
gagpol
result
increas
virion
associ
gag
process
intermedi
suggest
defect
pr
activ
cherri
et
al
liao
wang
quillent
et
al
studi
suggest
modul
rt
dimer
context
gagpol
may
neg
impact
pr
activ
matur
import
rt
region
gagpol
rt
matur
viral
particl
product
demonstr
studi
rt
point
mutat
prevent
rt
heterodimer
homodimer
mutat
compon
highli
conserv
tryptophan
repeat
motif
connect
subdomain
block
rt
dimer
vitro
tachedjian
et
al
tachedjian
et
al
express
manifest
defect
revers
transcript
aberr
process
rt
low
level
infect
wapl
et
al
mutat
locat
rt
primer
grip
region
prevent
rt
dimer
decreas
gagpol
stabil
tachedjian
et
al
yu
et
al
mutat
reduc
pr
incorpor
virion
increas
accumul
gag
process
intermedi
result
product
noninfecti
viru
particl
tachedjian
et
al
yu
et
al
exampl
demonstr
potenti
target
gagpol
embed
rt
block
matur
apart
classic
nnrti
exist
class
unconvent
nnrti
bind
rt
inhibit
enzym
activ
decreas
overal
stabil
heterodim
without
dissoci
complex
sluiscrem
et
al
sluiscrem
tachedjian
sluiscrem
et
al
camarasa
et
al
tsaot
deriv
tertbutyldimethylsilyl
thymin
destabilis
rt
heterodim
homodim
induc
chang
rt
dimer
interfac
sluiscrem
et
al
rodriguezbarrio
et
al
put
bind
site
rt
dimer
interfac
overlap
part
nnrti
bind
pocket
rodriguezbarrio
et
al
resist
mutat
tsao
drug
readili
gener
cell
cultur
indic
drug
specif
inhibitor
rt
balzarini
et
al
tsao
repres
first
class
small
molecul
destabil
rt
heterodim
preclin
studi
demonstr
pharmacolog
profil
tsao
inhibitor
unfavour
clinic
develop
camarasa
et
al
nacylhydrazon
deriv
n
hydrazon
bbnh
bind
dna
polymeras
rnase
h
domain
rt
inhibit
enzymat
activ
rt
arion
et
al
similar
tsao
bbnh
prevent
rt
activ
destabil
dissoci
subunit
bbnh
deriv
bind
dna
polymeras
domain
alon
suffici
induc
dimer
destabil
sluiscrem
tachedjian
recent
resolv
structur
rt
bound
bbnh
deriv
confirm
bind
site
close
proxim
distinct
polymeras
activ
site
nnibp
thought
bbnh
destabil
rt
heterodim
induc
chang
primergrip
motif
import
region
rt
dimer
stabil
himmel
et
al
srivastava
et
al
target
rt
dimer
interfac
possibl
unconvent
nnrti
may
affect
late
stage
viru
replic
particular
tsao
drug
destabil
homodim
may
also
perturb
process
rt
matur
heterodim
arguabl
even
target
rt
domain
gagpol
interfer
pr
activ
howev
possibl
effect
describ
elucid
impact
nonclass
nnrti
rt
matur
mechan
destabil
would
advantag
design
potent
inhibitor
rt
function
rt
matur
interestingli
sever
classic
nnrti
shown
confer
concentr
depend
increas
rt
heterodim
format
correspond
loss
rt
polymeras
function
tachedjian
et
al
venezia
et
al
efavirenz
efv
strong
enhanc
rt
dimer
also
enhanc
format
homodim
tachedjian
et
al
exact
mechan
increas
rt
subunit
interact
unknown
suspect
bind
efv
rt
mediat
conform
chang
subunit
promot
interact
tachedjian
et
al
efv
also
demonstr
capac
enhanc
homodimer
vitro
model
pol
protein
induc
bacteri
express
system
sluiscrem
et
al
tachedjian
et
al
recent
demonstr
nnrti
enhanc
gagpol
dimer
result
prematur
pr
activ
decreas
viral
particl
releas
figueiredo
et
al
transfect
cell
efv
increas
gag
gagpol
process
caus
decreas
viral
particl
product
similar
effect
observ
nnrti
significantli
enhanc
homodimer
nrti
figueiredo
et
al
henc
nnrti
potent
enhanc
rt
dimer
also
affect
late
stage
viral
replic
repres
novel
inhibitori
mechan
drug
howev
concentr
requir
mediat
effect
two
three
order
magnitud
higher
concentr
block
rt
function
like
due
reduc
bind
affin
nnrti
propos
target
rt
domain
gagpol
strategi
identifi
drug
potent
inhibitor
late
stage
viral
lifecycl
could
identifi
screen
molecul
enhanc
gagpol
dimer
screen
could
enhanc
incorpor
mutat
rt
known
confer
decreas
suscept
current
nnrti
order
select
drug
potenti
block
nnrti
resist
strain
two
strategi
utilis
gener
peptid
design
target
rt
dimer
interfac
order
block
rt
function
includ
peptid
correspond
region
known
import
role
rt
dimer
debys
de
clercq
depolli
et
al
divita
et
al
morri
et
al
morri
et
al
success
peptid
correspond
rt
residu
deriv
highli
conserv
tryptophan
repeat
motif
depolli
et
al
interact
destabl
rt
heterodim
homodim
similar
unconvent
nnrti
unabl
induc
rt
dissoci
depolli
et
al
base
peptid
potent
suppressor
replic
noncytotox
concentr
morri
et
al
method
inhibit
infect
cell
elucid
howev
given
induc
rt
subunit
dissoci
suggest
act
late
stage
viru
replic
prevent
format
activ
rt
heterodim
morri
et
al
ration
strategi
utilis
avail
rt
structur
direct
design
manufactur
mimet
peptid
target
subunit
interact
recent
develop
campbel
et
al
hosokawa
et
al
studi
led
synthesi
peptid
also
target
rt
connect
subdomain
inhibit
rt
activ
micromolar
concentr
campbel
et
al
cell
stabli
transfect
peptid
protect
infect
concentr
depend
manner
due
inhibit
revers
transcript
observ
decreas
dna
hosokawa
et
al
catalys
insert
viral
dna
host
chromosom
thu
inhibit
earli
crucial
step
viru
life
cycl
also
implic
revers
transcript
nuclear
import
preintegr
complex
viral
assembl
bud
engelman
et
al
hehl
et
al
despit
numer
role
replic
new
approach
inhibit
viral
replic
focus
target
catalyt
activ
requir
provir
dna
integr
two
inhibitor
enter
clinic
trial
cotel
makhija
shown
efficaci
phase
iii
clinic
trial
stephenson
sinc
express
part
gagpol
agent
bind
domain
polyprotein
like
impact
late
stage
replic
consist
notion
mutat
report
effect
virion
format
shin
et
al
truncat
cterminu
gagpol
result
aberr
virion
core
structur
reduct
overal
level
cellassoci
viral
gag
suggest
defect
gagpol
process
engelman
et
al
bukovski
gottling
requir
oligomer
activ
therefor
inhibitor
function
mediat
effect
negat
subunit
interact
also
like
interfer
viral
assembl
would
manifest
interf
gagpolgagpol
interact
lead
subsequ
effect
pr
activ
muriaux
et
al
regard
peptid
inhibitor
dimer
report
howev
effect
late
stage
viru
lifecycl
remain
determin
maroun
et
al
zhao
et
al
certain
host
cell
factor
incorpor
virion
interact
domain
gagpol
cellular
factor
implic
affect
late
stage
viru
life
cycl
integras
interactor
identifi
yeast
twohybrid
screen
host
cell
protein
interact
yung
et
al
yung
et
al
kalpana
et
al
mutant
abrog
interact
cell
defici
exhibit
substanti
reduct
viral
product
yung
et
al
affect
sever
step
replic
ariumi
et
al
sorin
et
al
yung
et
al
also
packag
particl
kalpana
et
al
fragment
minim
ininteract
domain
inhibit
viral
product
yung
et
al
yung
et
al
inhibitori
effect
product
mediat
bind
ectop
express
gagpol
embed
furthermor
stabl
express
transdomin
mutant
inhibit
infect
tcell
repres
potenti
lead
develop
inhibitor
late
stage
replic
yung
et
al
intracellular
degrad
misfold
damag
unwant
protein
mediat
proteosom
multisubunit
proteolyt
complex
schubert
et
al
protein
tag
proteolyt
destruct
coval
attach
chain
ubiquitin
polypeptid
lysin
residu
protein
schubert
et
al
proteosom
inhibitor
inhibit
late
stage
lifecycl
interf
viral
particl
releas
matur
schubert
et
al
decreas
bud
also
demonstr
retrovirus
express
pppi
ptap
contain
late
domain
use
ypdl
type
late
domain
schubert
et
al
ott
et
al
effect
depend
viral
particl
assembl
site
ie
cytoplasm
plasma
membran
monoubiquitin
gag
ott
et
al
addit
decreas
viral
particl
releas
virion
releas
cell
treat
proteosom
inhibitor
approxim
decreas
infect
schubert
et
al
impact
proteosom
inhibitor
depend
activ
pr
presenc
late
domain
independ
vpu
function
inhibit
matur
bud
observ
revers
zlll
also
known
irrevers
lactocystin
proteosom
inhibitor
schubert
et
al
proteosom
inhibitor
also
interfer
activ
viral
infect
factor
vif
antivir
function
apolipoprotein
b
mrnaedit
enzym
catalyt
polypeptidelik
viru
produc
cell
stopak
et
al
sheehi
et
al
mehl
et
al
yu
et
al
wildtyp
virus
express
vif
abl
prevent
incorpor
virion
promot
degrad
cytoplasm
produc
cell
inhibit
incorpor
viru
prevent
hypermut
newli
synthes
viral
dna
follow
infect
target
cell
due
c
u
modif
minu
stand
dna
synthesi
mediat
proteosom
inhibitor
interfer
vif
depend
degrad
suggest
inhibitor
imped
mechan
use
viru
evad
innat
defenc
host
cell
stopak
et
al
sheehi
et
al
mehl
et
al
yu
et
al
target
essenti
cellular
process
like
proteosom
anticip
cytotox
well
toler
vivo
nevertheless
highli
specif
proteosom
inhibitor
epoxomicin
also
inhibit
matur
well
toler
mice
meng
et
al
proteosom
inhibitor
approv
last
resort
treatment
multipl
myeloma
associ
advers
effect
kane
et
al
use
proteosom
inhibitor
infect
individu
need
consid
context
potenti
risk
benefit
net
effect
inhibit
replic
proteosom
inhibitor
also
enhanc
earli
step
viru
lifecycl
prevent
degrad
revers
transcript
complex
mediat
schwartz
et
al
wu
et
al
wei
et
al
accessori
protein
vpu
kda
type
integr
membran
protein
indispens
viral
pathogenesi
li
et
al
vpu
play
two
distinct
role
viral
lifecycl
includ
regul
host
cell
receptor
willey
et
al
enhanc
viral
particl
releas
cell
surfac
latter
associ
ion
channel
form
properti
schubert
et
al
vpu
uniqu
virus
binett
cohen
interestingli
two
close
relat
retrovirus
siv
lack
vpu
less
pathogen
bour
strebel
role
vpu
viral
bud
process
coupl
ion
channel
form
properti
predict
pentamer
structur
compos
five
transmembran
domain
grice
et
al
vpu
ion
channel
thought
function
alter
electr
potenti
plasma
membran
altern
overcom
host
restrict
factor
viral
releas
neil
et
al
vpu
member
viral
ion
channel
protein
call
viroporin
structur
similar
ion
channel
protein
influenza
gonzalez
carrasco
hout
et
al
interest
featur
vpu
role
viral
particl
releas
nondivid
cell
macrophag
deora
ratner
regard
rate
host
cell
prolifer
determin
factor
vpu
mediat
viral
particl
releas
deora
ratner
analogu
amilorid
sodium
channel
blocker
inhibit
vpu
ion
channel
activ
amilorid
analogu
n
nhexamethylen
amilorid
hma
n
ndimethyl
amilorid
dma
inhibit
vpu
mediat
viru
bud
viral
replic
macrophag
ewart
et
al
ewart
et
al
inhibitori
effect
observ
absenc
cytotox
analog
exhibit
strong
inhibit
replic
measur
viral
level
cultur
supernat
ewart
et
al
hma
suppress
viral
cultur
supernat
undetect
level
day
cultur
ewart
et
al
amilorid
analogu
demonstr
activ
macrophag
fail
inhibit
replic
tcell
ewart
et
al
nevertheless
vpu
ion
channel
inhibitor
potenti
use
combin
therapi
target
viral
reservoir
drugresist
variant
amilorid
deriv
current
pursu
drug
develop
biotron
limit
sydney
nsw
australia
repres
promis
antiretrovir
therapeut
although
evalu
vivo
efficaci
present
challeng
sinc
inhibit
replic
appear
restrict
nonprolifer
cell
recent
studi
also
suggest
rimantadin
ion
channel
blocker
influenza
virus
use
lead
compound
design
vpu
inhibitor
rimantadin
amantadin
belong
class
polycycl
amin
activ
ion
channel
influenza
vpu
hout
et
al
studi
indic
mutat
histidin
residu
alanin
result
rimantadin
sensit
vpu
ion
channel
demonstr
potenti
class
inhibitor
ion
channel
blocker
hout
et
al
vpu
also
implic
interact
certain
host
cell
restrict
factor
interfer
viral
particl
egress
host
cell
protein
vpubind
protein
ubp
suggest
neg
factor
viru
assembl
callahan
et
al
bour
strebel
ubp
protein
exhibit
competit
bind
vpu
gag
callahan
et
al
handley
et
al
overexpress
ubp
report
significantli
suppress
viral
particl
releas
suggest
ubp
neg
factor
requir
displac
gag
vpu
callahan
et
al
suggest
vpu
mediat
effect
viral
egress
facilit
membran
target
gag
precursor
handley
et
al
harila
et
al
neil
et
al
support
notion
vpudefect
particl
appear
intern
membranebound
compart
suggest
gag
target
defect
klimkait
et
al
anoth
host
cell
restrict
factor
implic
viral
releas
acidsensit
potassium
channelform
protein
regul
viral
infect
hsu
et
al
due
structur
homolog
vpu
suggest
form
heterooligom
vpu
interfer
mediat
conduct
vpu
ion
channel
function
hsu
et
al
delin
host
cell
factor
interact
vpu
requir
order
design
small
molecul
inhibitor
inhibit
viral
particl
releas
recent
year
major
advanc
made
understand
retrovirus
releas
infect
cell
earli
report
mutat
late
domain
inhibit
virion
particl
releas
gottling
et
al
moreov
ptap
sequenc
encompass
amino
acid
critic
viru
particl
product
huang
et
al
ptap
motif
bind
specif
host
cell
protein
tumor
suppressor
gene
result
recruit
compon
endosom
sort
complex
requir
transporti
escrti
verplank
et
al
martinserrano
et
al
garru
et
al
demirov
et
al
delet
ptap
motif
result
approxim
reduct
particl
releas
similarli
overexpress
silenc
abolish
viral
egress
garru
et
al
demirov
et
al
goilagaur
et
al
nmr
structur
analysi
amino
acid
peptid
deriv
encompass
ptap
motif
complex
uev
domain
reveal
ptap
motif
bind
groov
bind
creat
two
main
pocket
ap
pocket
contact
amino
acid
p
pocket
bind
amino
acid
peptid
pornillo
et
al
pornillo
et
al
interrupt
viral
host
proteinprotein
interact
compound
bind
pocket
compet
gag
would
potenti
inhibit
viral
particl
releas
rate
cellcel
transmiss
bieniasz
far
one
report
describ
synthesi
select
small
molecul
five
fold
better
bind
capac
peptid
contain
sequenc
wild
type
ptap
motif
l
domain
liu
et
al
studi
author
describ
approach
previous
employ
obtain
peptoid
key
prolin
residu
substitut
glycin
nterminu
parent
prorich
sequenc
order
improv
bind
specif
src
homolog
domain
nguyen
et
al
similarli
prolin
rich
ptap
domain
consid
good
candid
nsubstitut
glycin
residu
approach
studi
bind
affin
kd
wildtyp
ptap
contain
peptid
liu
et
al
bind
constant
highest
affin
peptoidhydrazon
design
respect
highest
affin
peptoid
hydrazon
found
nbutylcontain
peptid
fivefold
increas
bind
affin
compar
wildtyp
ptap
peptid
capac
peptid
compet
gag
bind
effect
egress
vitro
vivo
remain
determin
although
disrupt
viralhost
cell
interact
attract
approach
abolish
virion
releas
infect
interf
host
cell
machineri
could
major
consequ
host
bieniasz
multifunct
protein
play
critic
role
cell
prolifer
shown
studi
conduct
defici
mice
ruland
et
al
involv
cellular
transcript
play
central
role
endosom
sort
cargo
protein
destin
degrad
proteasom
recruit
endosom
sort
pathway
specif
interact
host
cell
protein
hepatocyt
growth
factorregul
tyrosin
kinas
substrat
hr
bind
psap
motif
lu
et
al
disrupt
interact
inhibit
deliveri
epiderm
growth
factor
receptor
egfr
late
endosom
recruit
believ
mimic
hr
order
enter
endosom
sort
pathway
negoti
releas
infect
cell
pornillo
et
al
thu
target
would
result
accumul
protein
plasma
membran
disrupt
protein
sort
within
infect
cell
specif
inhibit
bud
target
late
domain
bind
site
requir
preferenti
inhibit
bind
compar
hr
consider
progress
made
understand
late
step
viral
lifecycl
lead
product
infecti
viral
particl
mani
process
reli
protein
protein
interact
either
viral
protein
viral
protein
host
cell
factor
interact
host
viral
protein
either
role
facilit
viru
replic
observ
viral
necessari
overcom
neg
effect
host
viru
replic
mediat
vif
also
reli
posttransl
modif
mediat
host
cell
machineri
order
viral
polyprotein
traffick
appropri
compart
cell
viral
assembl
bud
arguabl
one
effect
drug
use
treat
infect
individu
pr
inhibitor
block
viral
matur
underscor
effect
target
late
stage
viru
replic
nevertheless
strategi
describ
review
inhibit
viru
replic
cell
cultur
assay
requir
improv
potenc
specif
deliveri
viabl
use
clinic
